The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does BiTE® AMG 701 compare to other immunotherapies for heavily pretreated patients?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Suzanne Lentzsch, Columbia University, New York, US. We asked, How does the bispecific T-cell engager (BiTE®) AMG 701 compare to other immunotherapies for heavily pretreated patients?

In this video, Lentzsch discusses the first-in-human clinical trial assessing AMG 701, an anti-B-cell maturation antigen BiTE® molecule, in a heavily pretreated relapsed/refractory patient population. She then compares AMG 701 with other immunotherapies and comments that it is too early to give a final verdict on the best antibody.

 

Share: